We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 01, 2020

Empagliflozin Effects by Baseline Cardiometabolic Categories

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Empagliflozin Treatment Effects Across Categories of Baseline HbA1c, Body Weight and Blood Pressure as an Add-on to Metformin in Patients With Type 2 Diabetes
Diabetes Obes Metab 2020 Oct 20;[EPub Ahead of Print], SE Inzucchi, MJ Davies, K Khunti, P Trivedi, JT George, I Zwiener, OE Johansen, N Sattar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading